Pular para o conteúdo
Merck

A7655

Atenolol

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Atenolol

Sinônimo(s):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Slide 1 of 1
Faça login para ver os preços organizacionais e de contrato.

Selecione um tamanho

Preço e disponibilidade não estão disponíveis no momento.

Sobre este item

Fórmula empírica (Notação de Hill):
C14H22N2O3
Número CAS:
29122-68-7
Peso molecular:
266.34
NACRES:
NA.77
PubChem Substance ID:
24277748
UNSPSC Code:
12352200
EC Number:
249-451-7
MDL number:
MFCD00057645

Documentos Principais

Visualizar Toda a Documentação

Pular para

Assistência Técnica
Precisa de ajuda? Nossa equipe de cientistas experientes está à sua disposição.
Estamos aqui para ajudar

Nome do produto

Atenolol, ≥98% (TLC), powder

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

originator

AstraZeneca

Quality Level

200

Gene Information

human ... ADRB1(153)
rat ... Adrb1(24925)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Comparar Itens Semelhantes

Ver Comparação Total

Mostrar diferenças

1 of 4

Este Item
PHR1909A-0725.05416
Atenolol ≥98% (TLC), powder

Sigma-Aldrich

A7655

Atenolol

Atenolol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1909

Atenolol

Atenolol solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-072

Atenolol solution

(+/-)-Atenolol

Sigma-Aldrich

5.05416

(+/-)-Atenolol

assay

≥98% (TLC)

assay

-

assay

-

assay

≥98% (TLC)

form

powder

form

powder

form

liquid

form

powder

Quality Level

200

Quality Level

300

Quality Level

300

Quality Level

100

solubility

H2O: 0.3 mg/mL, ethanol: 3.4 mg/mL, DMSO: 18 mg/mL

solubility

-

solubility

-

solubility

DMSO: 18 mg/mL

color

white to off-white

color

-

color

-

color

white

originator

AstraZeneca

originator

-

originator

-

originator

-

Application

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem/physiol Actions

Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Shelf-life of the solid is at least three years.

related product

Nº do produto
Descrição
Preços

Classe de armazenamento

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
BCCL7859
BCCK4552
BCCG8517
BCCD4543
BCCC4638

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
Tzu-Heng Huang et al.
International journal of molecular sciences, 22(21) (2021-11-14)
Thoracic aortic aneurysm (TAA) formation is a multifactorial process that results in diverse clinical manifestations and drug responses. Identifying the critical factors and their functions in Marfan syndrome (MFS) pathogenesis is important for exploring personalized medicine for MFS. Methylenetetrahydrofolate reductase
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Exibir todos os documentos relacionados
1 Review This action will navigate to reviews.

Questions

1 Review This action will navigate to reviews.

Reviews

Active Filters

  1. 1 Ratings-only review

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica